{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T06:29:32Z","timestamp":1694068172981},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2002,6,1]],"date-time":"2002-06-01T00:00:00Z","timestamp":1022889600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Surgical Oncology"],"published-print":{"date-parts":[[2002,6]]},"DOI":"10.1007\/bf02557273","type":"journal-article","created":{"date-parts":[[2007,2,7]],"date-time":"2007-02-07T17:52:29Z","timestamp":1170870749000},"page":"486-492","source":"Crossref","is-referenced-by-count":16,"title":["Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma"],"prefix":"10.1007","volume":"9","author":[{"given":"Eddy C.","family":"Hsueh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Essner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leland J.","family":"Foshag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald L.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02557273_CR1","first-page":"233","volume":"64","author":"DL Morton","year":"1968","unstructured":"Morton DL, Malmgren RA, Homes EC, Ketcham AS. Demonstration of antibodies against human malignant melanoma by immunofluorescence.Surgery 1968;64:233\u201340.","journal-title":"Surgery"},{"key":"BF02557273_CR2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/bmj.3.5670.547","volume":"3","author":"MG Lewis","year":"1969","unstructured":"Lewis MG, Ikonopisov RL, Nairn RC et al. Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease.BMJ 1969;3:547\u201352.","journal-title":"BMJ"},{"key":"BF02557273_CR3","first-page":"189","volume":"35","author":"AJ Bodurtha","year":"1975","unstructured":"Bodurtha AJ, Chee DO, Laucius JF, et al. Clinical and immunological significance of human melanoma cytotoxic antibody.Cancer Res 1975;35:189\u201393.","journal-title":"Cancer Res"},{"key":"BF02557273_CR4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/BF02523659","volume":"7","author":"EC Hsueh","year":"2000","unstructured":"Hsueh EC, Gupta RK, Yee R, et al. Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma?Ann Surg Oncol 2000;7:232\u20138.","journal-title":"Ann Surg Oncol"},{"key":"BF02557273_CR5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1749-6632.1964.tb40991.x","volume":"114","author":"TC Everson","year":"1964","unstructured":"Everson TC. Spontaneous regression of cancer.Ann N Y Acad Sci 1964;114:721\u201335.","journal-title":"Ann N Y Acad Sci"},{"key":"BF02557273_CR6","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/S0264-410X(00)00490-4","volume":"19","author":"D Berd","year":"2001","unstructured":"Berd D. Autologous, hapten-modified vaccine as a treatment for human cancers.Vaccine 2001;19:2565\u201370.","journal-title":"Vaccine"},{"key":"BF02557273_CR7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0733-8635(05)70009-7","volume":"16","author":"JC Bystryn","year":"1998","unstructured":"Bystryn JC. Vaccines for melanoma. Design strategies and clinical results.Dermatol Clin 1998;16:269\u201375.","journal-title":"Dermatol Clin"},{"key":"BF02557273_CR8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nm0398-321","volume":"4","author":"SA Rosenberg","year":"1998","unstructured":"Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.Nat Med 1998;4: 321\u20137.","journal-title":"Nat Med"},{"key":"BF02557273_CR9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1072-7515(98)00097-0","volume":"187","author":"MK Wallack","year":"1998","unstructured":"Wallack MK, Sivanandham M, Balch CM, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.J Am Coll Surg 1998;187:69\u201377.","journal-title":"J Am Coll Surg"},{"key":"BF02557273_CR10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/canjclin.46.4.225","volume":"46","author":"DL Morton","year":"1996","unstructured":"Morton DL, Barth A. Vaccine therapy for malignant melanoma.CA Cancer J Clin 1996;46:225\u201344.","journal-title":"CA Cancer J Clin"},{"key":"BF02557273_CR11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00000658-199210000-00010","volume":"216","author":"DL Morton","year":"1992","unstructured":"Morton DL, Foshag, LJ, Hoon DSB, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.Ann Surg 1992;216:463\u201382.","journal-title":"Ann Surg"},{"key":"BF02557273_CR12","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/(SICI)1097-0142(19990515)85:10<2160::AID-CNCR10>3.0.CO;2-0","volume":"85","author":"EC Hsueh","year":"1999","unstructured":"Hsueh EC, Nathanson L, Foshag LJ, et al. Active specific immunotherapy with polyvalent melanoma cell vaccine in patients with in-transit melanoma metastases.Cancer 1999;85:2160\u201369.","journal-title":"Cancer"},{"key":"BF02557273_CR13","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1200\/JCO.1998.16.9.2913","volume":"16","author":"EC Hsueh","year":"1998","unstructured":"Hsueh EC, Gupta RK, Qi K, et al. Correlation of specific immune responses with survival in patients receiving melanoma cell vaccine.J Clin Oncol 1998;16:2913\u201320.","journal-title":"J Clin Oncol"},{"key":"BF02557273_CR14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/BF02303828","volume":"5","author":"EC Hsueh","year":"1998","unstructured":"Hsueh EC, Famatiga E, Gupta RK, et al. Enhancement of complement-dependent cytotoxicity by melanoma cell vaccine: correlation with disease-free survival.Ann Surg Oncol 1998;5:595\u2013602.","journal-title":"Ann Surg Oncol"},{"key":"BF02557273_CR15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1523-1747.1999.00493.x","volume":"112","author":"T Takahashi","year":"1999","unstructured":"Takahashi T, Johnson TD, Nishinaka Y, et al. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients.J Invest Dermatol 1999;112:205\u20139.","journal-title":"J Invest Dermatol"},{"key":"BF02557273_CR16","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1046\/j.1523-1747.1998.00411.x","volume":"111","author":"T Okamoto","year":"1998","unstructured":"Okamoto T, Irie RF, Fujii S, et al. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.J Invest Dermatol 1998; 111:1034\u20139.","journal-title":"J Invest Dermatol"},{"key":"BF02557273_CR17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/BF02305761","volume":"3","author":"RC Jones","year":"1996","unstructured":"Jones RC, Kelley M, Gupta RK, et al. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.Ann Surg Oncol 1996;3:437\u201345.","journal-title":"Ann Surg Oncol"},{"key":"BF02557273_CR18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/(SICI)1096-9098(199908)71:4<209::AID-JSO1>3.0.CO;2-2","volume":"71","author":"DW Ollila","year":"1999","unstructured":"Ollila DW, Hsueh EC, Stern SL, Morton DL. Metastasectomy for recurrent stage IV melanoma.J Surg Oncol 1999;71:209\u201313.","journal-title":"J Surg Oncol"},{"key":"BF02557273_CR19","first-page":"611","volume":"25","author":"AD Chan","year":"1998","unstructured":"Chan AD, Morton DL. Active immunotherapy with allogeneic tumor cell vaccines: present status.Semin Oncol 1998;25:611\u201322.","journal-title":"Semin Oncol"},{"issue":"Suppl 8","key":"BF02557273_CR20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1034\/j.1600-0749.13.s8.29.x","volume":"13","author":"Y Kawakami","year":"2000","unstructured":"Kawakami Y, Suzuki Y, Shofuda T et al. T cell immune responses against melanoma and melanocytes in cancer and autommunity.Pigment Cell Res 2000;13(Suppl 8):163\u20139.","journal-title":"Pigment Cell Res"},{"key":"BF02557273_CR21","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1084\/jem.192.11.1637","volume":"192","author":"C Yee","year":"2000","unstructured":"Yee C, Thompson JA, Roche P, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.J. Exp Med 2000;192:1637\u201344.","journal-title":"J. Exp Med"},{"key":"BF02557273_CR22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3322\/canjclin.49.2.101","volume":"49","author":"DL Morton","year":"1999","unstructured":"Morton DL, Ollila DW, Hsueh EC et al. Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma.CA Cancer J Clin 1999;49:101\u201316.","journal-title":"CA Cancer J Clin"},{"key":"BF02557273_CR23","volume-title":"Immunology","author":"I Roitt","year":"1998","unstructured":"Roitt I, Brostoff J, Male D.Immunology. 5th ed. Edinburgh: Mosby, 1998.","edition":"5th ed."},{"key":"BF02557273_CR24","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/1097-0142(19821015)50:8<1656::AID-CNCR2820500833>3.0.CO;2-L","volume":"50","author":"LG Feun","year":"1982","unstructured":"Feun LG, Gutterman J, Burgess MA, et al. The natural history of resectable metastatic melanoma (stage IVA melanoma).Cancer 1982;50:1656\u201363.","journal-title":"Cancer"},{"key":"BF02557273_CR25","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/1097-0142(19850901)56:5<1222::AID-CNCR2820560544>3.0.CO;2-A","volume":"56","author":"TK Overett","year":"1985","unstructured":"Overett TK, Shiu MH. Surgical treatment of distant metastatic melanoma: indications and results.Cancer 1985;56:1222\u201330.","journal-title":"Cancer"},{"key":"BF02557273_CR26","first-page":"256","volume":"107","author":"NS Karp","year":"1990","unstructured":"Karp NS, Boyd A, DePan HJ, et al. Thoracotomy for metastatic malignant melanoma of the lung.Surgery 1990;107:256\u201361.","journal-title":"Surgery"},{"key":"BF02557273_CR27","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/0002-9610(91)90254-B","volume":"162","author":"GD Branum","year":"1991","unstructured":"Branum GD, Seigler HF. Role of surgical intervention in the management of intestinal metastases from malignant melanoma.Am J Surg 1991;162:428\u201331.","journal-title":"Am J Surg"},{"key":"BF02557273_CR28","first-page":"295","volume":"115","author":"CP Karakousis","year":"1994","unstructured":"Karakousis CP, Velez A, Driscoll BA. Metastasectomy in malignant melanoma.Surgery 1994;115:295\u2013302.","journal-title":"Surgery"},{"key":"BF02557273_CR29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0002-9610(98)00041-5","volume":"175","author":"WS Fletcher","year":"1998","unstructured":"Fletcher WS, Pommier RF, Lum S, et al. Surgical treatment of metastatic melanoma.Am J Surg 1998;175:413\u20137.","journal-title":"Am J Surg"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02557273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02557273\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02557273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T22:14:34Z","timestamp":1558304074000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02557273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["BF02557273"],"URL":"https:\/\/doi.org\/10.1007\/bf02557273","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6]]}}}